[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339230-105":59,"doc-detail-339230-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","preclinical-evaluation-and-first-in-dog-clinical-trials-of-pbmc-expanded-natural-killer-cells-for-adoptive-immunotherapy-in-dogs-with-cancer","Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer","","Natural killer (NK) cells are cytotoxic lymphoid effectors that can recognize diverse cancer targets without prior sensitization, supporting their use in cellular adoptive immunotherapy. Companion dogs develop spontaneous cancers with an intact immune system, providing a clinically relevant model. The study evaluates NK activation and expansion using unmanipulated PBMCs and reports preliminary first-in-dog trial activity, demonstrating safety and early efficacy signals in canine melanoma and osteosarcoma.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/preclinical-evaluation-and-first-in-dog-clinical-trials-of-pbmc-expanded-natural-killer-cells-for-adoptive-immunotherapy-in-dogs-with-cancer/339230/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/preclinical-evaluation-and-first-in-dog-clinical-trials-of-pbmc-expanded-natural-killer-cells-for-adoptive-immunotherapy-in-dogs-with-cancer/339230.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of this study?","Question",{"text":112,"@type":113},"To assess NK activation, expansion, and preliminary clinical activity in first-in-dog clinical trials using a novel PBMC-based manufacturing approach for adoptive immunotherapy in dogs with cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were NK cells manufactured for the preclinical and clinical evaluations?",{"text":117,"@type":113},"CD5-depleted cells and unmanipulated PBMCs were co-cultured for 14 days, with phenotype, cytotoxicity, and cytokine secretion measured; samples were also analyzed by 3’-Tag-RNA-Seq.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key safety and early efficacy outcomes in the first-in-dog trials?",{"text":121,"@type":113},"Autologous and allogeneic PBMC-derived NK cells were expanded successfully, resulting in no serious adverse events, along with preliminary efficacy signals in dogs with melanoma and osteosarcoma.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339230,1790193862,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Open access Original research  \n Preclinical evaluation and first-in-dog  \nclinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer  \nAryana M Razmara  ,1 Lauren E Farley,1 Rayna M Harris,2 Sean J Judge,1 Marshall Lammers,1 Khurshid R Iranpur,1 Eric G Johnson,3 Cordelia Dunai,4 William J Murphy  ,4 C Titus Brown,2 Robert B Rebhun  ,3 Michael S Kent,3 Robert J Canter  1  \nTo cite: Razmara AM, Farley LE, Harris RM, et al. Preclinical evaluation and first-in-dog clinical trials of PBMCexpanded natural killer cells for adoptive immunotherapy in dogs with cancer. Journal for ImmunoTherapy of Cancer 2024;12:e007963 . doi:10 . 1136/ jitc-2023-007963  \nAccepted 29 March 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \n1Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA  \n2Department Population Health and Reproduction, University of California Davis School of Veterinary Medicine, Davis, California, USA  \n3Department of Surgical and Radiological Sciences, University of California Davis School of Veterinary Medicine, Davis, California, USA  \n4Department of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA  \nCorrespondence to  \nDr Robert J Canter; [rjcanter@ucdavis.edu](rjcanter@ucdavis.edu)  \nABSTRACT  \nBackground Natural killer (NK) cells are cytotoxic cells capable of recognizing heterogeneous cancer targets without prior sensitization, making them promising prospects for use in cellular immunotherapy. Companion dogs develop spontaneous cancers in the context of an intact immune system, representing a valid cancer immunotherapy model. Previously, CD5 depletion of peripheral blood mononuclear cells (PBMCs) was used in dogs to isolate a CD5dim-expressing NK subset prior to coculture with an irradiated feeder line, but this can limit the yield of the final NK product. This study aimed to assess NK activation, expansion, and preliminary clinical activity in first-in-dog clinical trials using a novel system with unmanipulated PBMCs to generate our NK cell product. Methods Starting populations of CD5-depleted cells and PBMCs from healthy beagle donors were co-cultured for 14 days, phenotype, cytotoxicity, and cytokine secretion were measured, and samples were sequenced using the 3’-Tag-RNA-Seq protocol. Co-cultured human PBMCs and NK-isolated cells were also sequenced for comparative analysis. In addition, two first-in-dog clinical trials were performed in dogs with melanoma and osteosarcoma using autologous and allogeneic NK cells, respectively, to establish safety and proof-of-concept of this manufacturing approach.  \nResults Calculated cell counts, viability, killing, and cytokine secretion were equivalent or higher in expanded NK cells from canine PBMCs versus CD5-depleted cells, and immune phenotyping confirmed a CD3-NKp46+ product from PBMC-expanded cells at day 14. Transcriptomic analysis of expanded cell populations confirmed upregulation of NK activation genes and related pathways, and human NK cells using well-characterized NK markers closely mirrored canine gene expression patterns. Autologous and allogeneic PBMC-derived NK cells were successfully expanded for use in first-in-dog clinical trials, resulting in no serious adverse events and preliminary efficacy data. RNA sequencing of PBMCs from dogs receiving allogeneic NK transfer showed patientunique gene signatures with NK gene expression trends in response to treatment.  \nConclusions Overall, the use of unmanipulated PBMCs appears safe and potentially effective for canine NK  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ Natural killer (NK) cell adoptive transfer has the potential to overcome barriers to success in immunotherapy.\u003Cbr>⇒ Spontaneous canine models of cancer provide an avenue to optimize NK cell-based treatments, but further investig","cbCaigAbQaP9Q75G","https://ap.wps.com/l/cbCaigAbQaP9Q75G","pdf",7304077,17,"English","# ABSTRACT\n# WHAT IS ALREADY KNOWN ON THIS TOPIC\n# WHAT THIS STUDY ADDS\n# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY\n# BACKGROUND","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To assess NK activation, expansion, and preliminary clinical activity in first-in-dog clinical trials using a novel PBMC-based manufacturing approach for adoptive immunotherapy in dogs with cancer.\"},{\"question\":\"How were NK cells manufactured for the preclinical and clinical evaluations?\",\"answer\":\"CD5-depleted cells and unmanipulated PBMCs were co-cultured for 14 days, with phenotype, cytotoxicity, and cytokine secretion measured; samples were also analyzed by 3’-Tag-RNA-Seq.\"},{\"question\":\"What were the key safety and early efficacy outcomes in the first-in-dog trials?\",\"answer\":\"Autologous and allogeneic PBMC-derived NK cells were expanded successfully, resulting in no serious adverse events, along with preliminary efficacy signals in dogs with melanoma and osteosarcoma.\"}]","Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer | PDF",1790028878,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7af58b0ce1e29efa88025347ebd001b.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce8529fcae46a38365fdf45427235fd1.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cbf5189666d547b6e28ab36ba54491c.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/977b917d398c39a529c4295299704508.webp",980,1306]